SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
Health economic consequences of reducing salt intake and replacing saturated fat with polyunsaturated fat in the adult Finnish population: estimates based on the FINRISK and FINDIET studies
6 references·0 citing·29 second hop
Health economic consequences of reducing salt intake and replacing saturated fat with polyunsaturated fat in the adult Finnish population: estimates based on the FINRISK and FINDIET studies (2011)Health economic consequences of reducing …Guidelines for Conducting Pharmaceutical Budget Impact Analyses for Submission to Public Drug Plans in Canada (2008)Guidelines for Conducting Pha…Principles of Good Practice for Budget Impact Analysis: Report of the ISPOR Task Force on Good Research Practices—Budget Impact Analysis (2007)Principles of Good Practice f…The Impact of 29 Chronic Conditions on Health-related Quality of Life: A General Population Survey in Finland Using 15D and EQ-5D (2006)The Impact of 29 Chronic Cond…Monitoring as a Motivation for IPO Underpricing (2004)Monitoring as a Motivation fo…Probabilistic Analysis of Cost-Effectiveness Models: Choosing between Treatment Strategies for Gastroesophageal Reflux Disease (2002)Probabilistic Analysis of Cos…Cost-effectiveness analysis. (1993)Cost-effectiveness analysis.EuroQol - a new facility for the measurement of health-related quality of life (1990)Econometric Analysis of Cross Section and Panel Data (2001)Impact of psychiatric disorders on health-related quality of life: general population survey (2007)Diagnostic and Statistical Manual of Mental Disorders (2013)Japanese population norms for preference-based measures: EQ-5D-3L, EQ-5D-5L, and SF-6D (2015)Population norms for the EQ-5D-3L: a cross-country analysis of population surveys for 20 countries (2018)RISK, UNCERTAINTY, AND DIVERGENCE OF OPINION (1977)The Structure of Corporate Ownership: Causes and Consequences (1985)Why new issues are underpriced (1986)Underpricing, ownership dispersion, and aftermarket liquidity of IPO stocks (2007)On the Decision to Go Public with Dual Class Stock (2009)Underpricing, board structure, and ownership (2013)Principles of Good Practice for Decision Analytic Modeling in Health-Care Evaluation: Report of the ISPOR Task Force on Good Research Practices—Modeling Studies (2003)International society for pharmacoeconomics and outcomes research (2006)Global Spending on Orphan Drugs in France, Germany, the UK, Italy and Spain during 2007 (2010)Budget impact analysis in economic evaluation: a proposal for a clearer definition (2011)A Methodological Review of US Budget-Impact Models for New Drugs (2016)Costs, effects and C/E‐ratios alongside a clinical trial (1994)Net Health Benefits (1998)A National Catalog of Preference-Based Scores for Chronic Conditions in the United States (2005)Incremental cost-effectiveness ratios (ICERs): The silence of the lambda (2005)Methods for the Economic Evaluation of Health Care Programmes (2005)Optimal Cost-Effectiveness Decisions: The Role of the Cost-Effectiveness Acceptability Curve (CEAC), the Cost-Effectiveness Acceptability Frontier (CEAF), and the Expected Value of Perfection Information (EVPI) (2008)Development of WHO guidelines on generalized cost-effectiveness analysis (2000)The death of cost‐minimization analysis? (2001)Health and Social Justice (2004)Current Status and Future Prospects of Clinical Psychology (2008)Propuesta de guía para la evaluación económica aplicada a las tecnologías sanitarias (2009)Mental disorders and medical comorbidity. (2011)
this work references cited by second hop

References

  • 1993Cost-effectiveness analysis.816 cited
  • 2007Principles of Good Practice for Budget Impact Analysis: Report of the ISPOR Task Force on Good Research Practices—Budget Impact Analysis751 cited
  • 2006The Impact of 29 Chronic Conditions on Health-related Quality of Life: A General Population Survey in Finland Using 15D and EQ-5D413 cited
  • 2002Probabilistic Analysis of Cost-Effectiveness Models: Choosing between Treatment Strategies for Gastroesophageal Reflux Disease413 cited
  • 2008Guidelines for Conducting Pharmaceutical Budget Impact Analyses for Submission to Public Drug Plans in Canada80 cited
  • 2004Monitoring as a Motivation for IPO Underpricing59 cited

Cited by

No citing works inside the corpus for this window.

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work